171 related articles for article (PubMed ID: 12946247)
1. Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies.
Dereure O
Expert Opin Drug Saf; 2003 Sep; 2(5):467-73. PubMed ID: 12946247
[TBL] [Abstract][Full Text] [Related]
2. [New drugs in oncology and skin toxicity].
Mateus C; Robert C
Rev Med Interne; 2009 May; 30(5):401-10. PubMed ID: 19299041
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
Hu JC; Sadeghi P; Pinter-Brown LC; Yashar S; Chiu MW
J Am Acad Dermatol; 2007 Feb; 56(2):317-26. PubMed ID: 17141360
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of cutaneous toxicities to EGFR inhibitors.
Lacouture ME
Nat Rev Cancer; 2006 Oct; 6(10):803-12. PubMed ID: 16990857
[TBL] [Abstract][Full Text] [Related]
5. Skin moisturization for xerosis related to targeted anticancer therapies.
Gisondi P; Girolomoni G
J Am Acad Dermatol; 2015 Jul; 73(1):e33. PubMed ID: 26089072
[No Abstract] [Full Text] [Related]
6. Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies".
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Jul; 73(1):e35-6. PubMed ID: 26089073
[No Abstract] [Full Text] [Related]
7. Chemotherapeutic agents and the skin: An update.
Heidary N; Naik H; Burgin S
J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
[TBL] [Abstract][Full Text] [Related]
8. From cellular receptors to transduction-transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation?
Dayer JM; Molnarfi N; Burger D
Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S83-96. PubMed ID: 16187943
[TBL] [Abstract][Full Text] [Related]
9. Skin adverse events in recently approved targeted therapies in solid malignancies.
Habre M; Salloum A; Habre SB; Abi Chebl J; Dib R; Kourie HR
Future Oncol; 2019 Jan; 15(3):331-343. PubMed ID: 30523696
[TBL] [Abstract][Full Text] [Related]
10. How to manage hypersensitivity reactions to biological agents?
Barbaud A; Granel F; Waton J; Poreaux C
Eur J Dermatol; 2011; 21(5):667-74. PubMed ID: 21742594
[TBL] [Abstract][Full Text] [Related]
11. [Cytokines as biomarkers of the patients state severity and prognostication in burns: new therapeutic possibilities of existing approaches in treatment. Part 2].
Kovalenko OM; Mal'tsev DB; Kazmirchuk VIe; Kozynets HP
Klin Khir; 2012 Jan; (1):57-61. PubMed ID: 22642092
[No Abstract] [Full Text] [Related]
12. [Cutaneous side effects of antiangiogenic agents].
Robert C
Bull Cancer; 2007 Jul; 94 Spec No():S260-4. PubMed ID: 17846013
[TBL] [Abstract][Full Text] [Related]
13. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2.
Bremmer M; Deng A; Gaspari AA
Dermatitis; 2009; 20(5):243-56. PubMed ID: 19807998
[TBL] [Abstract][Full Text] [Related]
14. [Cutaneous adverse effects of TNFalpha antagonists].
Failla V; Sabatiello M; Lebas E; de Schaetzen V; Dezfoulian B; Nikkels AF
Rev Med Liege; 2012; 67 Spec No():3-7. PubMed ID: 22690479
[TBL] [Abstract][Full Text] [Related]
15. Anti-EGFR therapy update: clinical experience and adverse event insights.
Harari PM
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):3-4. PubMed ID: 16736977
[No Abstract] [Full Text] [Related]
16. Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?
Jorgensen C; Apparailly F; Sany J
Ann Rheum Dis; 1999 Mar; 58(3):136-41. PubMed ID: 10364909
[No Abstract] [Full Text] [Related]
17. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T
Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
[TBL] [Abstract][Full Text] [Related]
18. Cellular signalling pathways: new targets in leukaemia therapy.
Ravandi F; Talpaz M; Kantarjian H; Estrov Z
Br J Haematol; 2002 Jan; 116(1):57-77. PubMed ID: 11841398
[No Abstract] [Full Text] [Related]
19. Biologic agents in the therapy of inflammatory rheumatic diseases, including therapeutic antibodies, cytokines, and cytokine antagonists.
Kalden JR
Curr Opin Rheumatol; 1994 May; 6(3):281-6. PubMed ID: 8060762
[TBL] [Abstract][Full Text] [Related]
20. [Adverse drug reactions induced by molecular target therapy].
Kano Y
Arerugi; 2007 Dec; 56(12):1485-91. PubMed ID: 18195551
[No Abstract] [Full Text] [Related]
[Next] [New Search]
